Immune Pharmaceuticals Inc (IMNP) Enters into Letter of Intent with Pint Pharma GmnH; Shares on the Rise

It’s a very rewarding trading day for investors in Immune Pharmaceuticals Inc (NASDAQ:IMNP) with shares up over 50%, making the stock Wall Street’s bull of the day. The reason? The antibody development firm announced that it has entered into a letter of intent with Pint Pharma GmnH, which binds the parties to seek agreement regarding an exclusive license by Pint of the rights to commercialize Immune’s oncology pipeline drug Ceplene throughout Latin America, including Argentina, Brazil, Chile, Colombia and Mexico. In conjunction with the anticipated final agreement, Pint will make an investment of $4 million into Immune Pharma’s oncology subsidiary, Cytovia, Inc. to be used by Cytovia exclusively for oncology related activities.

Immune and Pint target closing a final agreement within 30 days. Pursuant to the anticipated final agreement, Pint will be responsible for registration of Ceplene in Latin American countries based on the existing European marketing authorization and will carry out the full commercialization of the licensed product in the territory, including Ceplene registration, pricing and reimbursement, and sales and marketing activities.

Ceplene has been approved in Europe for the maintenance of first remission in patients with Acute Myeloid Leukemia (AML) in combination with interleukin-2 (IL-2). According to Pint, there are approximately 10,000 new cases of AML diagnosed per year in Latin America and there is currently no approved treatment for the maintenance of  AML remission.

“We are excited about the possibility of partnering with Pint Pharma, a market leader in Latin America with strong commercialization capabilities in the field of oncology. Pint Pharma’s desire to bring Ceplene/IL-2 immunotherapy to patients in Latin America  complements our strategy,” said Dr Daniel Teper, CEO of Immune.

“Adding Ceplene to our portfolio of products will further leverage our experience and presence in the oncology field in Latin America,” said David Munoz, Chief Executive Office at Pint. “We are delighted to potentially have Immune as a committed partner to help strengthen our product portfolio.”

Dr. Massimo Radaelli, Executive Chairman of Pint Pharma, has served as an independent director of Ariad Pharmaceuticals Inc. until  2016. He has held the position of President and CEO of Dompe International SA and previously held senior executive positions at Roche, Menarini and DuPont Merck.

“We are very enthusiastic about this potential partnership with Immune and Cytovia which is developing much needed therapies in oncology,” said Dr. Radaelli. “We believe we can leverage the high unmet need  for relapse preventive immunotherapy to potentially accelerate the registration and commercial availability of Ceplene in Latin America for patients suffering from AML.”

Immune Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It engages in the development and commercialization of targeted therapeutics, including mAbs nanotherapeutics and antibody drug conjugates, for the treatment of inflammatory diseases and cancer. The company acquires, develops and commercialises prescription drug products.


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts